Newsfeeds - Spark Newswire

3 minute read

38 Stocks Moving In Thursday’s Mid-Day Session

Today, 3:33 AM

Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares climbed 34.6% to $4.1993 after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia.

AFI

1 minute read

Barclays Maintains Overweight on Cellectis, Lowers Price Target to $7

By Benzinga Newsdesk

Today, 3:33 AM

Barclays analyst Gena Wang maintains Cellectis (NASDAQ:CLLS) with a Overweight and lowers the price target from $9 to $7.

CLLS

57 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 3:33 AM

On Friday, 1043 companies hit new 52-week lows.

AAOI

1 minute read

Natural Killer Cell Therapy Focused-Cytovia Turns To SPAC Merger For Public Market Debut

By Vandana Singh

Today, 3:33 AM

About 14 months after inking a natural killer cell deal with Cellectis SA (NASDAQ:CLLS), Cytovia plans to list on NASDAQ via…

CLLS

3 minute read

Cellectis To Present Preclinical Data On UCART20x22 At AACR Apr. 10

By Bill Haddad

Today, 3:33 AM

Preclinical data demonstrated POC with robust in vitro and in vivo anti-tumor activity UCART20x22 allogeneic dual CAR T has been designed and engineered on the TRAC / CD52

CLLS

32 minute read

Stocks That Hit 52-Week Lows On Monday

By Benzinga Insights

Today, 3:33 AM

On Monday, 524 stocks hit new 52-week lows.

AAL

22 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 3:33 AM

On Friday, 368 stocks hit new 52-week lows.

AAL

1 minute read

Earnings

Recap: Cellectis Q4 Earnings

By Benzinga Insights

Today, 3:33 AM

Cellectis (NASDAQ:CLLS) reported its Q4 earnings results on Thursday, March 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Cellectis beat estimated earnings by 47.83%, reporting an EPS of $-0.48 versus an estimate of $-0.92.

CLLS

1 minute read

UPDATE: Cellectis Q4 Adj. EPS $(0.48) Beats $(0.92) Estimate

By Benzinga Newsdesk

Today, 3:33 AM

Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.92) by 47.83 percent. This is a 45.45 percent increase over losses of $(0.88) per share from the

CLLS

9 minute read

Earnings Scheduled For March 3, 2022

By Benzinga Insights

Today, 3:33 AM

Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million.

ABUS